Sensei Biotherapeutics (SNSE) Competitors $0.53 +0.02 (+4.17%) As of 01/17/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends SNSE vs. PDSB, SPRO, OPTN, TNXP, DYAI, IVVD, ACHL, ICCC, XLO, and ALVRShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include PDS Biotechnology (PDSB), Spero Therapeutics (SPRO), OptiNose (OPTN), Tonix Pharmaceuticals (TNXP), Dyadic International (DYAI), Invivyd (IVVD), Achilles Therapeutics (ACHL), ImmuCell (ICCC), Xilio Therapeutics (XLO), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. PDS Biotechnology Spero Therapeutics OptiNose Tonix Pharmaceuticals Dyadic International Invivyd Achilles Therapeutics ImmuCell Xilio Therapeutics AlloVir PDS Biotechnology (NASDAQ:PDSB) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Which has more volatility and risk, PDSB or SNSE? PDS Biotechnology has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Which has stronger earnings & valuation, PDSB or SNSE? PDS Biotechnology is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$42.94M-$1.16-1.25Sensei BiotherapeuticsN/AN/A-$34.10M-$1.19-0.45 Does the MarketBeat Community believe in PDSB or SNSE? PDS Biotechnology received 43 more outperform votes than Sensei Biotherapeutics when rated by MarketBeat users. However, 80.00% of users gave Sensei Biotherapeutics an outperform vote while only 69.61% of users gave PDS Biotechnology an outperform vote. CompanyUnderperformOutperformPDS BiotechnologyOutperform Votes7169.61% Underperform Votes3130.39% Sensei BiotherapeuticsOutperform Votes2880.00% Underperform Votes720.00% Does the media favor PDSB or SNSE? In the previous week, PDS Biotechnology and PDS Biotechnology both had 1 articles in the media. PDS Biotechnology's average media sentiment score of 0.95 beat Sensei Biotherapeutics' score of -0.50 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Overall Sentiment PDS Biotechnology Positive Sensei Biotherapeutics Negative Is PDSB or SNSE more profitable? Sensei Biotherapeutics' return on equity of -53.86% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -139.57% -67.22% Sensei Biotherapeutics N/A -53.86%-46.91% Do insiders and institutionals have more ownership in PDSB or SNSE? 26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 9.5% of PDS Biotechnology shares are owned by company insiders. Comparatively, 22.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer PDSB or SNSE? PDS Biotechnology presently has a consensus target price of $11.67, indicating a potential upside of 704.60%. Sensei Biotherapeutics has a consensus target price of $4.33, indicating a potential upside of 717.61%. Given Sensei Biotherapeutics' higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPDS Biotechnology and Sensei Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.33M$6.34B$5.21B$8.93BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-0.459.8989.8017.35Price / SalesN/A315.771,248.2377.32Price / CashN/A61.4443.8235.97Price / Book0.206.055.324.79Net Income-$34.10M$154.90M$122.69M$225.00M7 Day Performance3.41%-1.70%-0.17%1.52%1 Month Performance23.26%1.93%3.49%4.88%1 Year Performance-33.09%3.14%25.79%20.12% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.3882 of 5 stars$0.53+4.2%$4.33+717.6%-33.0%$13.33MN/A-0.4540Short Interest ↑News CoverageGap DownPDSBPDS Biotechnology1.5828 of 5 stars$1.42+0.4%$11.67+724.5%-66.2%$52.93MN/A-1.2220News CoverageGap UpSPROSpero Therapeutics4.6348 of 5 stars$0.93-4.7%$5.00+435.5%-35.5%$50.90M$89.87M13.34150OPTNOptiNose4.3819 of 5 stars$5.01-5.5%$26.00+419.0%-67.5%$50.40M$75.67M-17.89190Analyst ForecastNews CoverageGap UpTNXPTonix Pharmaceuticals3.0893 of 5 stars$0.26-7.4%$53.50+20,620.4%-97.3%$48.26M$11.29M0.0050Analyst ForecastShort Interest ↑Gap DownDYAIDyadic International3.143 of 5 stars$1.63-1.2%$6.00+268.1%-3.2%$48.23M$3.36M-7.097Short Interest ↓Positive NewsGap UpIVVDInvivyd3.0849 of 5 stars$0.40-11.7%$7.89+1,877.3%-90.8%$47.72M$11.56M-0.20100Short Interest ↑ACHLAchilles Therapeutics2.6591 of 5 stars$1.16-2.1%$4.00+244.8%+35.9%$47.68MN/A-0.70250Short Interest ↑News CoveragePositive NewsICCCImmuCell0.1079 of 5 stars$5.33+2.7%N/A-2.0%$47.50M$23.84M-10.6670Short Interest ↑News CoverageXLOXilio Therapeutics3.1757 of 5 stars$1.07-2.7%$4.00+273.8%+65.8%$47.04M$4.62M-0.6270Short Interest ↑Positive NewsALVRAlloVir1.5676 of 5 stars$0.40-8.2%N/A-41.5%$46.61MN/A-0.46110Stock SplitShort Interest ↓News CoverageHigh Trading Volume Related Companies and Tools Related Companies PDSB Alternatives SPRO Alternatives OPTN Alternatives TNXP Alternatives DYAI Alternatives IVVD Alternatives ACHL Alternatives ICCC Alternatives XLO Alternatives ALVR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNSE) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNSE Stock Alerts